Nocturnal intravenous gamma-hydroxybutyrate and sleep architecture in non-sedated intensive care unit patients: a polysomnographic experience - Scorecard - MDSpire
Clinical Scorecard: Effects of Overnight Intravenous Gamma-Hydroxybutyrate on Sleep Architecture in Unsedated ICU Patients: A Polysomnographic Study
At a Glance
Category
Detail
Condition
Clinical topic addressed by the source article: Effects of Overnight Intravenous Gamma-Hydroxybutyrate on Sleep Architecture in Uns sedated ICU Patients
Key Mechanisms
Mechanisms or clinical associations described in the source article.
Target Population
Population described in the source article.
Care Setting
General ICU; single-night polysomnographic assessment and overnight intravenous GHB administration
Key Highlights
In this small, uncontrolled study, eight GHB-treated patients had higher median sleep efficiency than five untreated patients (82% vs. 57%).
N3 sleep accounted for a greater proportion of total sleep time with GHB (58% vs. 8%); REM sleep was less frequent and absent in two GHB recipients.
Nurses judged all eight GHB-treated patients to have slept, compared with two of five untreated patients; reported sleep-quality scores were also higher with GHB.
Morning natraemia was higher after GHB (140 vs. 135 mmol/L); the authors note that a 9 g dose supplies roughly 70 mmol of sodium.
The authors report that findings require confirmation before routine use, given the small uncontrolled sample and potential confounding.
Guideline-Based Recommendations
Diagnosis
Management
In the study, selected patients received an intravenous GHB bolus followed by continuous infusion from 22:00 to 06:00; treatment was determined by the attending physician.
The authors state that the findings require confirmation before routine GHB use.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Thirteen ICU patients had interpretable recordings: all were calm and awake, non-delirious, and not invasively ventilated. Eight received GHB and five did not.
GHB recipients received a median 9.0 g (126 mg/kg) overnight. The study was small and uncontrolled, with no pretreatment polysomnographic recording; treatment was preferentially given to patients who had slept poorly the preceding night.
Clinical Best Practices
The authors caution that AASM criteria do not distinguish physiological slow-wave sleep from drug-induced delta activity.
The authors report that a 9 g sodium oxybate dose supplies roughly 70 mmol of sodium and state that daily electrolyte monitoring is warranted.
The authors identify the small uncontrolled sample, confounding by indication, possible regression to the mean, and absence of pretreatment recordings as study limitations.
The authors state that whether GHB-induced N3 sleep has the restorative properties of natural slow-wave sleep remains unknown.
